Author

Y. Kaku

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 5 Approach:experimental assay· 4 Organism:human· 4 Assay:proteomics· 2 Approach:statistical model· 1 Organism:virus· 1

Frequent Co-Authors

K. Sato· 4 shared K. Uriu· 4 shared The Genotype to Phenotype Japan (G2P-Japan) Consortium· 4 shared Y. Kosugi· 4 shared A. A. Hinay· 3 shared J. Ito· 3 shared J. Kuramochi· 3 shared A. Plianchaisuk· 2 shared

Activity by Year

2023-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

K. Sato

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Virological characteristics of the SARS-CoV-2 JN.1 variant

Y. Kaku, K. Okumura, M. Padilla-Blanco, Y. Kosugi, K. Uriu, A. A. Hinay, L. Chen, A. Plianchaisuk, K. Kobiyama, K. J. Ishii, The Genotype to Phenotype Japan (G2P-Japan) Consortium, J. Zahradnik, J. Ito, K. Sato

This study investigates the virological properties of the SARS-CoV-2 JN.1 variant, focusing on its mutations and potential immune evasion capabilities.

bioRxiv · Dec 8, 2023Microbiology

Antiviral humoral immunity against SARS-CoV-2 Omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals

Y. Kosugi, Y. Kaku, A. A. Hinay, Z. Guo, K. Uriu, M. Kihara, F. Saito, Y. Uwamino, J. Kuramochi, K. Shirakawa, A. Takaori-Kondo, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K. Sato

The paper assesses the humoral immune response to XBB.1.5 vaccine in infection-naive and XBB-infected individuals against various SARS-CoV-2 variants.

bioRxiv · Nov 29, 2023Microbiology

Virological characteristics of the SARS-CoV-2 Omicron HK.3 variant harboring the "FLip" substitution

Y. Kosugi, A. Plianchaisuk, O. Putri, K. Uriu, Y. Kaku, A. A. Hinay, L. Chen, J. Kuramochi, K. Sadamasu, K. Yoshimura, H. Asakura, M. Nagashima, The Genotype to Phenotype Japan (G2P-Japan) Consortium, J. Ito, K. Sato

This study investigates the virological properties of the SARS-CoV-2 HK.3 variant, a FLip variant with substitutions S:L455F and S:F456L, to assess its growth advantage.

bioRxiv · Nov 14, 2023 · PreprintMicrobiology

Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility

K. Tan, J. Chen, Y. Kaku, Y. Wang, L. Donius, R. A. Khan, X. Li, H. Richter, M. S. Seaman, T. Walz, W. Hwang, E. L. Reinherz, M. Kim

The paper shows that HIV-1 MPER-targeting antibodies generated by vaccines lack structural constraints needed to access the MPER, despite having bnAb-like paratopes.

Nature Communications · Nov 8, 2023Peer-reviewedImmunology

Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against Omicron subvariants including EG.5

Y. Kaku, Y. Kosugi, K. Uriu, J. Ito, J. Kuramochi, K. Sadamasu, K. Yoshimura, H. Asakura, M. Nagashima, The Genotype to Phenotype Japan (G2P-Japan) Consortium, K. Sato

This study evaluates the antiviral efficacy of XBB breakthrough infection sera against EG.5.1 and other Omicron subvariants, finding comparable neutralization titers and suggesting immune evasion is not the main driver of EG.5.1's spread.

bioRxiv · Aug 8, 2023 · PreprintMicrobiology